Stock listing

NASDAQ:NKTR Nektar Therapeutics Stock

Home listing (NASDAQ) of Nektar Therapeutics

Follow Nektar Therapeutics into a list and get an email when it puts out news.

Share price · NASDAQ:NKTR

$35.78 USD -1.94 (-5.1%)

Close on Oct 16, 2026

Since Jul 6, 2026 -51.1% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$35.62 – $38.05 USDOct 16, 2026
Volume
784,232 sharesOct 16, 2026
Market value
$1.22B USDAt the close on Oct 16, 2026 · price × 34.14M shares outstanding
Nektar Therapeutics logo
Ticker
NASDAQ:NKTR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Nektar Therapeutics (NASDAQ:NKTR) Q2 2026 Earnings Call

    Thu, Aug 13, 2026 · 5:00 PM ET

    Watch Transcript

  • Nektar Therapeutics (NASDAQ:NKTR) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 5:00 PM ET

    Watch Transcript

  • Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call

    Thu, Mar 12, 2026 · 5:00 PM ET

    Watch Transcript

Latest news

/UPDATE -- Nektar Therapeutics/

Oct 1, 2026

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

Oct 1, 2026

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

Sep 30, 2026

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Sep 28, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)

Aug 31, 2026

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Aug 25, 2026

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Aug 13, 2026

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Jul 28, 2026

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Jul 21, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2026

All Nektar Therapeutics news

Decks

Nektar Therapeutics on 6ix

Sector
Health care
Industry
Biotechnology
News releases
35 in the last 12 months · 187 in all · newest Oct 1, 2026 · oldest 2019
Calls
20 calls with a replay · 20 with a transcript · latest Aug 13, 2026
Decks
13 decks · latest Oct 1, 2026

Where Nektar Therapeutics is listed

ListingExchangeCountryCurrency
NASDAQ:NKTR · Home listing · This pageNASDAQUnited StatesUSD
gettex:ITH0gettexGermanyEUR
LS Exchange:A419UBLS ExchangeGermanyEUR
Tradegate:ITH0TradegateGermanyEUR
Lang & Schwarz:A419UBLang & SchwarzGermanyEUR
LSE:0UNLLSEUnited KingdomUSD
BMV:NKTRBMVMexicoMXN
BIVA:NKTRBIVAMexicoMXN
BOATS:NKTRBOATSUnited StatesUSD
BX Swiss:NKTRBX SwissSwitzerlandCHF
Dusseldorf:ITH0DusseldorfGermanyEUR
Frankfurt:ITH0FrankfurtGermanyEUR
Hamburg:ITH0HamburgGermanyEUR
Munich:ITH0MunichGermanyEUR
Stuttgart:ITH0StuttgartGermanyEUR
Hanover:ITH0HanoverGermanyEUR
Xetra:ITH0XetraGermanyEUR

Log in to ask 6ix AI your own questions about Nektar Therapeutics.